Suven Life Sciences Ltd (Suven) announced several poster presentations covering positive Pre-clinical and Clinical data of advanced clinical candidates and research molecules from their portfolio of new chemical entities (NCEs) at Neuroscience (SFN) 2022 hybrid conference, to be held in San Diego, California and virtually during 12-16, November 12-16, 2022.

Neuroscience 2022 is the annual meeting of the Society for Neuroscience (SfN) and around thirty thousand neuroscientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating.

About Suven Life Sciences:

Suven Life Sciences is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies. Suven has 4 clinical stage compounds, this Phase 3 masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type, ongoing Phase 2 samelisant (SUVN-G3031) for sleep disorders (Narcolepsy), Phase 2 ready ropanicant (SUVN-911) for Major Depressive Disorder (MDD) and Phase 2 ready usmarapride (SUVN-D4010) for cognitive disorders. Apart from this Suven has 11 molecules in development pipeline.

Disclaimer and Risk Statement

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.

Contact:

Tel: 91 40 2354 1142

Fax: 91 40 2354 1152

Email: info@suven.com

Web: www.suven.com

(C) 2022 Electronic News Publishing, source ENP Newswire